Mr. Shorrock was appointed President and Chief Executive Officer in September 2025 following the announcement of the Company’s pivot to a digital asset treasury strategy centered on BNB, a native cryptocurrency of the Binance blockchain ecosystem. He previously served as Chief Legal Officer and Executive Director of Business Development (April 2021-September 2025) and as President of LineaRx, the Company’s biotherapeutics subsidiary (December 2024-September 2025). During his tenure, Mr. Shorrock has led the Company’s legal, regulatory, risk mitigation, intellectual property and business development functions and has been instrumental in the development of the Company’s LineaDNA and LineaIVT platforms. Mr. Shorrock previously served as general and intellectual property counsel to the Company (November 2016-April 2019).
Prior to rejoining the Company in 2021, Mr. Shorrock practiced in the intellectual property groups at Lowndes, Drosdick, Doster, Kantor & Reed, P.A. (2020-2021) and Allen, Dyer, Doppelt & Gilchrist, P.A. (2019-2020). Earlier in his career, he was an associate at New Jersey law firms focused on intellectual property and complex commercial transactions.
Mr. Shorrock holds a B.A. in Biology from Franklin and Marshall College and a J.D., with a concentration in intellectual property, from Seton Hall University Law School.
Prior to being appointed as Chief Financial Officer of Applied DNA Sciences, Ms. Jantzen was the Controller for the Company since May of 2013. Ms. Jantzen is a certified public accountant with over 15 years financial and accounting experience.
Prior to joining the Company Ms. Jantzen was a senior manager at Marcum LLP, since June 9, 2014, where she managed multiple engagements and specialized in SEC policies, practices and procedures, including Sarbanes-Oxley compliance as well as valuations involving acquisitions. Ms Jantzen was named Who’s Who in Accounting/Audits by Long Island Business News in 2012.